共 38 条
- [31] The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsCANCER DISCOVERY, 2020, 10 (01) : 54 - 71Hallin, JillEngstrom, Lars D.Hargis, LaurenCalinisan, AndrewAranda, RuthBriere, David M.Sudhakar, NiranjanBowcut, VickieBaer, Brian R.Ballard, Joshua A.Burkard, Michael R.Fell, Jay B.Fischer, John P.Vigers, Guy P.Xue, YaohuaGatto, SoleFernandez-Banet, JulioPavlicek, AdamVelastagui, KarenChao, Richard C.Barton, JeremyPierobon, MariaelenaBaldelli, ElisaPatricoin, Emanuel F., IIICassidy, Douglas P.Marx, Matthew A.Rybkin, Igor I.Johnson, Melissa L.Ou, Sai-Hong IgnatiusLito, PiroPapadopoulos, Kyriakos P.Janne, Pasi A.Olson, PeterChristensen, James G.
- [32] JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6CANCER RESEARCH, 2022, 82 (12)Weiss, AndreasVoshol, HansPorta, Diana GrausFedele, CarmineSterker, DarioDe Kanter, RubenStringer, RowanWidmer, ToniLoo, AliceGuthy, Daniel A.Beyer, Kim S.Ostermann, NilsLeBlanc, CatherineGerspacher, MarcVaupel, AndreaSedrani, RichardZecri, FredericMaria, Saveur-MichelHofmann, FrancescoHammerman, PeterEngelman, JeffLorthiois, EdwigeCotesta, SimonaBrachmann, Saskia M.
- [33] RTK signaling and WT RAS activity as vulnerabilities in tumors with acquired resistance to GDP-state selective KRASG12C inhibitors in preclinical modelsCANCER RESEARCH, 2024, 84 (06)Solanki, Hitendra S.Shah, HarshitImbody, DenisDesai, BinaStewart, Paul A.Fang, BinStern, YaakovDarville, Lancia N.Koomen, John M.Marusyk, AndriyAhler, EthanAronchik, IdaSingh, MallikaHaura, Eric B.
- [34] Focal adhesive kinase inhibitor IN10018 sensitizes KRAS mutant cancer and overcomes drug resistance of KRAS G12C inhibitionCANCER RESEARCH, 2020, 80 (16)Zhang, BaoyuanZhang, YanZhang, JiangweiLiu, PingJiao, BoWang, ZaiqiRen, Ruibao
- [35] Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3KmTOR pathway inhibition and regulated by 4E-BP1CANCER RESEARCH, 2024, 84 (06)Meraz, Ismail M.Wu, ShuhongMajidi, MouradRen, ChenghuiXu, YiMeng, FengGao, LihuiSong, RenduoZhang, RanFang, BingliangWang, QiXi, YuanxinWang, JingJung, Sung YunRoth, Jack A.
- [36] Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung CancerCLINICAL CANCER RESEARCH, 2022, 28 (15) : 3318 - 3328Sabari, Joshua K.Velcheti, VamsidharShimizu, KazuhideStrickland, Matthew R.Heist, Rebecca S.Singh, MohiniNayyar, NaemaGiobbie-Hurder, AnitaDigumarthy, Subba R.Gainor, Justin F.Rajan, Anant P.Nieblas-Bedolla, EdwinBurns, Aaron C.Hallin, JillOlson, PeterChristensen, James G.Kurz, Sylvia C.Brastianos, Priscilla K.Wakimoto, Hiroaki
- [37] WEE1 inhibition enhances anti-tumor activity of sotorasib in KRASG12C-mutated non-small cell lung cancer in preclinical modelsCANCER SCIENCE, 2023, 114 : 1043 - 1043Yamamoto, GakuTanaka, KosukeKamata, RyoYamauchi, ToyohiroLiu, JieOhashi, AkihiroKobayashi, Susumu S.
- [38] CSF-1R inhibition with Pimicotinib (ABSK021) enhanced anti-tumor efficacy of KRASG12C inhibitors in preclinical non-small cell lung cancer mouse modelsCANCER RESEARCH, 2024, 84 (07)Zhang, NannanShen, BinLiu, ShenyanDai, ChengYing, HaiyanGuo, FushenZhu, ZhixuanShi, WanTu, MinWang, JieZhang, JieLiu, ManqiZhang, QiChen, Zhui